Kymera Therapeutics (KYMR) Net Cash Flow (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Net Cash Flow of -$212.9 million for Q1 2026, down 603.21% year-over-year from $42.3 million in Q1 2025, and down 187.23% quarter-over-quarter from $244.1 million in Q4 2025.
Kymera Therapeutics (KYMR) Net Cash Flow (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Net Cash Flow for 8 consecutive years, with -$212.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 603.21% year-over-year to -$212.9 million; the TTM figure through Mar 2026 stood at $54.1 million (up 1619.57% YoY), while the FY2025 annual figure was $236.8 million, up 2204.69% from the prior year.
- Net Cash Flow slipped to -$212.9 million in Q1 2026 per KYMR's latest filing, from $244.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $245.9 million in Q2 2025 and bottomed at -$222.9 million in Q3 2025.
- Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of $1.9 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow slumped 1470.87% — and 2025, when it jumped 2456.02%.
- Kymera Therapeutics' Net Cash Flow stood at -$87.2 million in 2022, then jumped by 133.16% to $28.9 million in 2023, then slumped by 66.99% to $9.5 million in 2024, then surged by 2456.02% to $244.1 million in 2025, then sank by 187.23% to -$212.9 million in 2026.
- Business Quant data shows KYMR's Net Cash Flow at -$212.9 million in Q1 2026, $244.1 million in Q4 2025, and -$222.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -19.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.60 Mn |
| Jun 30, 2026 | -19.60 Mn |
| Mar 31, 2026 | -212.91 Mn |
| Mar 31, 2026 | -212.91 Mn |
| Dec 31, 2025 | 244.07 Mn |
| Dec 31, 2025 | 244.07 Mn |
| Sep 30, 2025 | -222.90 Mn |
| Sep 30, 2025 | -222.90 Mn |
| Jun 30, 2025 | 245.86 Mn |
| Jun 30, 2025 | 245.86 Mn |
| Mar 31, 2025 | -30.28 Mn |
| Mar 31, 2025 | -30.28 Mn |
| Dec 31, 2024 | 9.55 Mn |
| Dec 31, 2024 | 9.55 Mn |
| Sep 30, 2024 | 43.05 Mn |
| Sep 30, 2024 | 43.05 Mn |
| Jun 30, 2024 | -25.88 Mn |
| Jun 30, 2024 | -25.88 Mn |
| Mar 31, 2024 | -16.44 Mn |
| Mar 31, 2024 | -16.44 Mn |